Press Release March 06, 2020

Orionis Biosciences Debuts with Collaboration with Novartis to Tackle Industry’s Most Challenging Protein Targets

The Life Sciences team advised Orionis Biosciences on its major drug discovery collaboration with Novartis. The goal of the four-year collaboration is to discover and design novel small molecule therapeutics, such as protein degraders, across various therapeutic areas, by broadly leveraging Orionis’ Allo-Glue™ technology platform. The terms of the collaboration include research funding, a convertible note investment, royalties and potential clinical milestones.

Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Its technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

Novartis is a leading global medicines company that uses innovative science and digital technologies to create transformative treatments in areas of great medical need.

The Goodwin team was led by Noelle Dubiansky, Bill Collins and Ian Longacre.

For additional details, please read the press release and articles in FierceBiotech and The Pharma Letter.